ClinicalTrials.gg
Status unknownNCT05737771Updated Feb 21, 2023

To Compare the Pharmacokinetic Characteristics of the Fixed-dose Combination Compared to the Loose Combination

A Phase 1 interventional study of DWC202213 and DWJ1563 in FDC and Diabetes Mellitus, Type 2, sponsored by Daewoong Pharmaceutical Co. LTD.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-21.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 4 of them phase 3. Enavogliflozin · Diabetes Mellitus, Type 2.

Planned enrollment
12th of 15
40 · median 140
Started
2023
with 3 others
Phase 1
3 of 15
1 open now
Registered
9th of 15
by date
Lead sponsor
12 of 15
Daewoong Pharmaceutical Co. LTD.

Among the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, this one is the 12th largest by planned enrollment, is one of 4 that started in 2023, is one of 3 in phase 1, and was the 9th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

About enavogliflozin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing enavogliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To compare the safety and pharmacokinetic properties between the administration of DWP16001 and DWC202213 as an individual drug, and the administration of DWJ1563 as a combination drug.

03

Conditions studied

  • FDC
  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Before participating in the clinical trial, a person who fully explained the purpose, content, and characteristics of the clinical trial drug and signed a written consent form approved by the IRB of Chungbuk University Hospital to participate in this study according to his free will.
  2. Healthy adults aged 19 or older at the time of screening.
  3. Those who weigh more than 50.0 kg in men and women, and have a (BMI) of 18.0 kg/m2 or more and less than 30.0 kg/m2 or less in women.

    • Body mass index (BMI) = Weight (kg) / [Height (m)] 2.

Exclusion criteria

Exclusion Criteria:

  1. A person with a history in liver, kidney, neuropsychiatric system, respiratory system, endocrine system, blood and tumor system, cardiovascular system (including orthostatic hypotension), digestive system, musculoskeletal system, etc.
  2. A history of gastrointestinal diseases (e.g., esophageal diseases such as Crohn's disease, esophageal achalasia, or esophageal stenosis) or surgery (except appendectomy, hernia).
  3. Those who are hypersensitive to other drugs (DPP-4 inhibitors, etc.) or have a history of clinically significant reactions, including DWP16001, DWC202213 and homogeneous (SGLT2 inhibitors)
  4. A person who shows the following results in the inspection items conducted during screening.

    • Blood , AST, Total > twice the .
    • The (e-GFR) \<90 mL/min/1.73 m2 (using the CKD-EPI method)
  5. After more than 3 minutes of rest, systolic blood pressure > 150 mmHg or \<90 mmHg, or diastolic blood pressure > 100 mmHg or \<60 mmHg, or pulse ≤ 40 bpm or ≥ 100 bpm in vital signs measured at the seat
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Other
    Group A

    administrate DWP16001 + DWC202213 at first period, and administrate DWJ1563 at second period

    Drug: DWC202213 · Drug: DWJ1563 · Drug: DWP16001

  • Other
    Group B

    administrate DWJ1563 at first period, and administrate DWP16001 + DWC202213 at second period

    Drug: DWC202213 · Drug: DWJ1563 · Drug: DWP16001

Interventions

  • DrugDWC202213

    DWC202213

  • DrugDWJ1563

    DWJ1563

  • DWP16001

06

What researchers measure

Primary outcomes

  1. AUC0-t of DWP16001

    AUC0-t of DWP16001

    Time frame: 0 to 24 hours

  2. Cmax of DWP16001

    Cmax of DWP16001

    Time frame: 0 to 24 hours

  3. AUC0-t of DWC202213

    AUC0-t of DWC202213

    Time frame: 0 to 24 hours

  4. Cmax of DWC202213

    Cmax of DWC202213

    Time frame: 0 to 24 hours

07

Study locations

1 of 1 sites recruiting
  • Chungbuk National University Hospital
    Cheongju-si, Seowon-gu 28644, Korea, Republic of
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Mar 2023, 2 months after the start.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 2 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2023
First posted
Feb 21, 2023
StartActual
Jan 25, 2023
Primary completionEst.
Mar 31, 2023
CompletionEst.
Jun 30, 2023
Last update
Feb 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05737771
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
Jan 25, 2023
Primary completion
Mar 31, 2023 (estimated)
Completion
Jun 30, 2023 (estimated)
Last update
Feb 21, 2023

Study contacts

Jun Gi Hwang, MD, PhD
Contact
jk_hwang@cbnuhctc.com
043 269 8747

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion